Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.83% |
| 2 | Financials | 7.37% |
| 3 | Consumer Discretionary | 6.6% |
| 4 | Communication Services | 5.05% |
| 5 | Healthcare | 4.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
2976
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.62M | ﹤0.01% |
182,858
-152,067
| -45% | -$1.34M |
|
2977
Ceco Environmental
CECO
$4.5B
| $1.62M | ﹤0.01% |
57,147
+19,152
| +50% | +$477K |
|
2978
Keros Therapeutics
KROS
$222M
| $1.62M | ﹤0.01% |
121,130
+61,270
| +102% | +$827K |
|
2979
PUT
Azenta
AZTA
$1.49B
| $1.62M | ﹤0.01% |
52,500
-95,500
| -65% | -$2.69M |
|
2980
Ramaco Resources Class A
METC
$667M
| $1.62M | ﹤0.01% |
122,928
+87,519
| +247% | +$836K |
|
2981
Vanguard Dividend Appreciation ETF
VIG
$115B
| $1.61M | ﹤0.01% |
7,880
+3,780
| +92% | +$733K |
|
2982
Coupang
CPNG
$29.3B
| $1.61M | ﹤0.01% |
53,747
-382,603
| -88% | -$9.8M |
|
2983
STAAR Surgical
STAA
$1.26B
| $1.61M | ﹤0.01% |
95,929
+12,793
| +15% | +$226K |
|
2984
CALL
Netflix
NFLX
$326B
| $1.61M | ﹤0.01% |
12,000
-581,000
| -98% | -$65.7M |
|
2985
Allegiant Air
ALGT
$2.36B
| $1.6M | ﹤0.01% |
29,200
-19,113
| -40% | -$985K |
|
2986
Hertz
HTZ
$838M
| $1.6M | ﹤0.01% |
234,912
-117,111
| -33% | -$731K |
|
2987
Esquire Financial Holdings
ESQ
$1.61B
| $1.6M | ﹤0.01% |
16,909
+4,423
| +35% | +$382K |
|
|
MTSR
2988
DELISTED
Metsera Inc
MTSR
| $1.6M | ﹤0.01% |
56,091
+36,203
| +182% | +$899K |
|
2989
BioLife Solutions
BLFS
$1.72B
| $1.59M | ﹤0.01% |
74,029
+25,648
| +53% | +$578K |
|
2990
Stoke Therapeutics
STOK
$2.02B
| $1.59M | ﹤0.01% |
139,900
+71,539
| +105% | +$679K |
|
2991
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.6B
| $1.59M | ﹤0.01% |
29,750
| – | – |
|
2992
Gorman-Rupp
GRC
$2.15B
| $1.58M | ﹤0.01% |
43,036
+15,190
| +55% | +$546K |
|
|
BFS
2993
Saul Centers
BFS
$850M
| $1.58M | ﹤0.01% |
46,155
+13,473
| +41% | +$454K |
|
2994
Merchants Bancorp
MBIN
$2.52B
| $1.58M | ﹤0.01% |
47,643
+25,137
| +112% | +$814K |
|
|
CLBR
2995
DELISTED
Colombier Acquisition Corp II
CLBR
| $1.57M | ﹤0.01% |
+101,860
| New | +$1.33M |
|
2996
CALL
Arcutis Biotherapeutics
ARQT
$3.3B
| $1.56M | ﹤0.01% |
+111,500
| New | +$1.56M |
|
|
JAMF
2997
DELISTED
Jamf
JAMF
| $1.56M | ﹤0.01% |
164,289
+49,940
| +44% | +$536K |
|
2998
Shore Bancshares
SHBI
$801M
| $1.56M | ﹤0.01% |
99,315
+19,643
| +25% | +$276K |
|
2999
Shutterstock
SSTK
$217M
| $1.56M | ﹤0.01% |
82,302
+27,090
| +49% | +$476K |
|
3000
Inspire Medical Systems
INSP
$1.68B
| $1.56M | ﹤0.01% |
11,993
-16,693
| -58% | -$2.42M |
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays deployed $35.4B of net new capital in Q2 2025, opening 461 new positions and adding to 2,914 existing holdings. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.54B trimmed.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.